Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Trelstar Articles

US FDA calls for heart/diabetes risk warnings for class of prostate cancer drugs

21 October 2010

France’s Ipsen sees 2009 sales up 7.6% and rise 8.2% in fourth quarter

2 February 2010

Ipsen's revenues up 6% on new US launches

9 February 2009

Ipsen updates on pipeline at its investor day; but more US delays for Reloxin

19 January 2009

US FDA accepts Debiopharm's Trelstar NDA for filing

24 November 2008

Ipsen's nine-month sales increase 7%

10 November 2008

Ipsen files for EU approval of six-month Decapeptyl

29 September 2008

Ipsen's first-half 2008 profit jumps 42%

8 September 2008

Ipsen's first-half sales beat expectations

11 August 2008

Ipsen's 2007 operating profit climbs 12%

10 March 2008

Six-month Decapeptyl similar to present forms

18 February 2008

Watson's 3rd-qtr 2007 revenue hits $594.7M

19 November 2007

Ipsen and Debiopharm extend Decapeptyl accord

5 November 2007

Watson's Trelstar is launched in USA

11 April 2005

Watson and Debiopharm sign deal for urology drugs

4 October 2004

Pfizer return another Pharmacia-licensed compound, Trelstar, to originator Debiopharm

8 December 2003

Debiopharm provides funding for Tulane Univ cancer research

3 February 2003

Debiopharm gets OK for prostate cancer drug in USA

6 July 2001

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS